Stay updated on Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.

Latest updates to the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page
- Check4 days agoChange DetectedThe page footer revision was updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedThe page now displays Revision: v3.5.0, replacing the previous Revision: v3.4.3.SummaryDifference0.0%

- Check47 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed, indicating a software version update with no changes to the study details.SummaryDifference0.0%

- Check68 days agoChange DetectedThe change is a revision update from v3.4.1 to v3.4.2 with no impact on study content or user-facing features. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check75 days agoChange DetectedPeking University People's Hospital was added as a study site in early 2026 after a prior removal in December 2025; the page revision also updated from v3.4.0 to v3.4.1.SummaryDifference0.1%

- Check90 days agoChange DetectedAdds a glossary toggle and makes small text/capitalization changes to metadata fields (e.g., Last Update statuses and No FEAR Act data). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Amivantamab & Lazertinib Combo in EGFR+ NSCLC Clinical Trial page.